LBA12 Tumour genomics in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib in the phase II ELIOS study

Abstract

Osimertinib, a 3rd-generation EGFR-TKI, is the preferred 1L treatment for EGFRm advanced NSCLC; however, resistance eventually develops. ELIOS (NCT03239340) characterised resistance mechanisms to 1L osimertinib with a primary objective comparing paired tumour tissue biopsies from baseline (BL) and after PD. We report exploratory analyses of concordance between tissue and plasma testing from BL and post-PD samples and PFS by detected plasma EGFRm at BL and by plasma EGFRm clearance at 8 wks post-treatment.